Atai Beckley/$ATAI
1D1W1MYTD1Y5YMAX
About Atai Beckley
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
- Ticker
- $ATAI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 99
- Headquarters
- New York, United States
- Website
- www.ataibeckley.com
Atai Beckley Metrics
BasicAdvanced
$2.7B
-
-$2.14
1.55
-
Price and volume
Market cap
$2.7B
Beta
1.55
52-week high
$7.45
52-week low
$3.27
Average daily volume
8.4M
Financial strength
Current ratio
8.578
Quick ratio
8.285
Long term debt to equity
0.89
Total debt to equity
2.429
Profitability
EBITDA (TTM)
-140.791
Gross margin (TTM)
-1,579.25%
Net profit margin (TTM)
-14,941.70%
Operating margin (TTM)
-3,169.54%
Effective tax rate (TTM)
0.44%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-39.03%
Return on equity (TTM)
-417.21%
Valuation
Price to revenue (TTM)
517
Price to book
15.47
Price to tangible book (TTM)
15.74
Price to free cash flow (TTM)
-17.803
Free cash flow yield (TTM)
-5.62%
Free cash flow per share (TTM)
-0.415
Growth
Revenue change (TTM)
93.68%
Earnings per share change (TTM)
210.49%
3-year revenue growth (CAGR)
154.28%
3-year earnings per share growth (CAGR)
32.15%
Atai Beckley News
AllArticlesVideos
Jim Cramer Isn't Sure If There's Upside In This Health Care Stock
Benzinga2 days ago
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
Business Wire3 weeks ago
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.